Bristol-Myers Financial Statements (BMY)
|
|
|
|
Report date
|
|
|
24.02.2020 |
10.02.2021 |
09.02.2022 |
14.02.2023 |
13.02.2024 |
|
31.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
26 145 |
42 518 |
46 385 |
46 159 |
45 006 |
|
47 435 |
|
Operating Income, bln rub |
|
|
5 464 |
5 128 |
10 159 |
10 328 |
16 598 |
|
12 717 |
|
EBITDA, bln rub |
? |
|
7 440 |
5 035 |
20 191 |
19 232 |
19 417 |
|
5 032 |
|
Net profit, bln rub |
? |
|
3 439 |
-8 995 |
6 994 |
6 327 |
8 025 |
|
-7 258 |
|
|
OCF, bln rub |
? |
|
8 067 |
14 052 |
16 207 |
13 066 |
13 860 |
|
15 003 |
|
CAPEX, bln rub |
? |
|
836.0 |
753.0 |
973.0 |
1 118 |
1 209 |
|
1 200 |
|
FCF, bln rub |
? |
|
7 231 |
13 299 |
15 234 |
11 948 |
12 651 |
|
13 803 |
|
Dividend payout, bln rub
|
|
|
2 679 |
4 075 |
4 396 |
4 634 |
4 744 |
|
4 805 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
77.9% |
0.00% |
62.9% |
73.2% |
59.1% |
|
-66.2% |
|
|
OPEX, bln rub |
|
|
12 154 |
28 568 |
27 908 |
26 918 |
34 313 |
|
22 822 |
|
Cost of production, bln rub |
|
|
8 078 |
11 773 |
9 940 |
10 137 |
10 693 |
|
14 034 |
|
R&D, bln rub |
|
|
6 148 |
11 143 |
10 195 |
9 509 |
9 299 |
|
9 842 |
|
Interest expenses, bln rub |
|
|
656.0 |
1 420 |
1 334 |
1 232 |
1 166 |
|
1 767 |
|
|
Assets, bln rub |
|
|
129 944 |
118 481 |
109 314 |
96 820 |
95 159 |
|
93 670 |
|
Net Assets, bln rub |
? |
|
51 598 |
37 822 |
35 946 |
31 061 |
29 430 |
|
17 142 |
|
Debt, bln rub |
|
|
47 538 |
51 673 |
45 596 |
40 717 |
41 464 |
|
51 400 |
|
Cash, bln rub |
|
|
12 346 |
14 546 |
13 979 |
9 123 |
12 280 |
|
8 094 |
|
Net debt, bln rub |
|
|
35 192 |
37 127 |
31 617 |
31 594 |
29 184 |
|
43 306 |
|
|
Ordinary share price, rub |
|
|
64.2 |
62.0 |
62.4 |
72.0 |
51.3 |
|
51.2 |
|
Number of ordinary shares, mln |
|
|
1 705 |
2 258 |
2 221 |
2 130 |
2 069 |
|
2 028 |
|
|
Market cap, bln rub |
|
|
109 444 |
140 064 |
138 479 |
153 254 |
106 160 |
|
103 874 |
|
EV, bln rub |
? |
|
144 636 |
177 191 |
170 096 |
184 848 |
135 344 |
|
147 180 |
|
Book value, bln rub |
|
|
-34 859 |
-35 968 |
-27 331 |
-26 443 |
-18 811 |
|
-31 573 |
|
|
EPS, rub |
? |
|
2.02 |
-3.98 |
3.15 |
2.97 |
3.88 |
|
-3.58 |
|
FCF/share, rub |
|
|
4.24 |
5.89 |
6.86 |
5.61 |
6.11 |
|
6.81 |
|
BV/share, rub |
|
|
-20.4 |
-15.9 |
-12.3 |
-12.4 |
-9.09 |
|
-15.6 |
|
|
EBITDA margin, % |
? |
|
28.5% |
11.8% |
43.5% |
41.7% |
43.1% |
|
10.6% |
|
Net margin, % |
? |
|
13.2% |
-21.2% |
15.1% |
13.7% |
17.8% |
|
-15.3% |
|
FCF yield, % |
? |
|
6.61% |
9.49% |
11.0% |
7.80% |
11.9% |
|
13.3% |
|
ROE, % |
? |
|
6.66% |
-23.8% |
19.5% |
20.4% |
27.3% |
|
-42.3% |
|
ROA, % |
? |
|
2.65% |
-7.59% |
6.40% |
6.53% |
8.43% |
|
-7.75% |
|
|
P/E |
? |
|
31.8 |
-15.6 |
19.8 |
24.2 |
13.2 |
|
-14.3 |
|
P/FCF |
|
|
15.1 |
10.5 |
9.09 |
12.8 |
8.39 |
|
7.53 |
|
P/S |
? |
|
4.19 |
3.29 |
2.99 |
3.32 |
2.36 |
|
2.19 |
|
P/BV |
? |
|
-3.14 |
-3.89 |
-5.07 |
-5.80 |
-5.64 |
|
-3.29 |
|
EV/EBITDA |
? |
|
19.4 |
35.2 |
8.42 |
9.61 |
6.97 |
|
29.2 |
|
Debt/EBITDA |
|
|
4.73 |
7.37 |
1.57 |
1.64 |
1.50 |
|
8.61 |
|
|
R&D/CAPEX, % |
|
|
735.4% |
1 480% |
1 048% |
850.5% |
769.1% |
|
820.2% |
|
|
CAPEX/Revenue, % |
|
|
3.20% |
1.77% |
2.10% |
2.42% |
2.69% |
|
2.53% |
|
| Bristol-Myers shareholders |
